Stock Analysis
Ipca Laboratories First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Ipca Laboratories (NSE:IPCALAB) First Quarter 2025 Results
Key Financial Results
- Revenue: ₹21.1b (up 33% from 1Q 2024).
- Net income: ₹1.92b (up 18% from 1Q 2024).
- Profit margin: 9.1% (down from 10% in 1Q 2024). The decrease in margin was driven by higher expenses.
- EPS: ₹7.58 (up from ₹6.42 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ipca Laboratories EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 21%.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India.
Performance of the Indian Pharmaceuticals industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 1 warning sign for Ipca Laboratories you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:IPCALAB
Ipca Laboratories
A pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia.